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Edited by Sandro SonninoAbstract Nitric oxide is associated with neuroﬁbrillary tangle,
which is composed mainly of hyperphosphorylated tau in the
brain of Alzheimers disease (AD). However, the role of nitric
oxide in tau hyperphosphorylation is unclear. Here we show that
nitric oxide produced by sodium nitroprusside (SNP), a recog-
nized donor of nitric oxide, induces tau hyperphosphorylation
at Ser396/404 and Ser262 in HEK293/tau441 cells with a simul-
taneous activation of glycogen synthase kinase-3b (GSK-3b).
Pretreatment of the cells with 10 mM lithium chloride (LiCl),
an inhibitor of GSK-3, 1 h before SNP administration inhibits
GSK-3b activation and prevents tau from hyperphosphorylation.
This is the ﬁrst direct evidence demonstrating that nitric oxide
induces AD-like tau hyperphosphorylation in vitro, and GSK-
3b activation is partially responsible for the nitric oxide-induced
tau hyperphosphorylation. It is suggested that nitric oxide may
be an upstream element of tau abnormal hyperphosphorylation
in AD.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Neuroﬁbrillary tangle (NFT) is one of the most prominent
histopathological features in Alzheimers disease (AD). Accu-
mulating evidence has demonstrated that abnormal hyper-
phosphorylation of microtubule-associated protein tau,
which aggregates into paired helical ﬁlaments (PHF), is the
main element of NFT [1]. However, it is still not fully under-
stood for the upstream eﬀectors and the mechanisms leading
to tau hyperphosphorylation and formation of neuroﬁbrillary
degeneration.
The following studies show that nitric oxide (NO) is relevant
with AD pathology: diﬀerent isoforms of nitric oxide synthase
(NOS), the enzyme catalyzing the production of nitric oxide,
are coexisted with NFT in tangle-bearing neurons of AD brain
[2–5]; the dimethylargininase, a zinc protein involved in the
regulation of nitric oxide synthase, is speciﬁcally elevated in
the cytoplasm of tangle- and pretangle-bearing neurons in
AD brain [6]; elevated p21ras expression in AD brain has been*Corresponding author. Fax: +86 27 83693883.
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vator of p21ras [7–9]; the co-expression of NOS and p21ras in
tangle-containing pyramidal neurons in early stage of AD has
also been reported [2]. More recently, it was reported that tau
hyperphosphorylation with a concurrent elevation of NOS
mRNA and protein level was observed by co-culture of Ab-
stimulated astrocytes with primary hippocampal neurons,
and this hyperphosphorylation of tau was eliminated by addi-
tion of NOS inhibitor [10]. All these studies strongly suggested
that nitric oxide may be involved in tau hyperphosphorylation
and neuroﬁbrillary tangle formation in AD brain. However,
the direct evidence for the role of nitric oxide in AD-like tau
hyperphosphorylation and the possible underlying mechanism
is still missing.
In the present study, we treated HEK293/tau441 cells
directly with sodium nitroprusside (SNP), a widely used nitric
oxide donor with short turnover [11–13]. We found that nitric
oxide induced tau hyperphosphorylation at Ser396/404 and
Ser262 with a concurrent GSK-3b activation, and inhibition
of GSK-3 eliminated the eﬀect of nitric oxide on tau hyper-
phosphorylation at Ser396/404.2. Materials and methods
2.1. Chemicals and antibodies
Rabbit polyclonal antibody (pAb) against GSK-3b and pAb against
phospho-GSK-3b (Serine 9) were purchased from Cell Signaling Tech-
nology, Inc. (Beverly, MA, USA). pAb Ser262 against tau phosphory-
lated at Ser262 was purchased from Biosource Inc, (Carmarillo, CA,
USA). pAb R134d against total tau was a gift from Dr. I Grundke-
Iqbal (New York State Institute for Basic Research, Staten Island,
NY, USA). Monoclonal antibody (mAb) PHF-1 against tau phos-
phorylated at Ser396/404 was a gift from Dr. P Davies (Albert Einstein
College of Medicine, Bronx, NY, USA). mAb Tau-1 against tau
unphosphorylated at Ser199/202 was from Chemicon International
Inc., (Temecula CA, USA). Goat anti-rabbit or goat anti-mouse per-
oxidase-conjugated secondary antibody, bicinchoninic acid kit and
chemiluminescent substrate kit were from Pierce Chemical Company
(Rockford, IL, USA). Sodium nitroprusside (SNP) was from Axxora
Life Science Inc. (San Diego, CA, USA). Nitric oxide detection kit
was purchased from Nanjing Jiancheng Biologic Engineering Co.
(Nanjing, P. R. China). mAb DM1A against a-tubulin, Lithium chlo-
ride (LiCl) and other chemicals were purchased from Sigma Chemical
Co. (St. Louis, MO, USA).3. Cell culture, treatment and lysate preparation
Human Embryonic Kidney (HEK) 293 cells (a kind gift
from Dr. H. Xu, The Burnham Institute, San Diego, USA)ation of European Biochemical Societies.
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(HEK293/Tau441) were seeded at 3 · 105 cells/well in 6-well
plates in DMEM in the presence of 200 lg/ml G418 with
10% fetal bovine serum (FBS, vol/vol) in a humidiﬁed atmo-
sphere of 5% CO2 at 37 C. Cells were used for experiment
36 h after seeding.
SNP was freshly resolved in medium before use and the cells
were cultured with diﬀerent concentrations of SNP for 15 or
30 min as indicated in the ﬁgures. To ensure the changes are
caused by nitric oxide but not by other chemicals released from
the donor, we designed the control experiments by using light-
depleted SNP, i.e., by extensive exposure of SNP to light for 14
days to eliminate nitric oxide from the product [14]. To con-
ﬁrm the eﬀect of GSK-3b, we used LiCl (10 mM) 1 h before
SNP administration to inhibit GSK-3.
Cells were rinsed twice in ice-cold phosphate-buﬀered saline
(PBS, pH 7.5) and lysed with buﬀer containing 50 mM Tris–Cl,
pH 8.0, 150 mM sodium chloride, 1% NP-40, 0.5% sodium
deoxycholate, 0.1% sodium dodecyl sulfate, 0.02% sodium
azide, 100 lg/ml phenylmethysulfonyl ﬂuoride, and 10 lg/ml
protease inhibitors (leupeptin, aprotinin and pepstatin) fol-
lowed by sonication for 5 s on ice. After centrifugation at
12000 · g for 5 min at 4 C, supernatants were fetched out
and added with equal volume of 2· Laemmli sample buﬀer
(125 mM Tris–HCl, pH 6.8, 8% SDS, 17% glycerol, 10%
b-mercaptoethanol, and 0.05% bromophenol blue). Samples
were boiled for 10 min before electrophoresis. Protein concen-
tration was estimated by BCA kit.4. Measurement of nitric oxide production
Nitric oxide generated from SNP was determined indirectly
through the measurement of nitrite, a stable metabolite of
nitric oxide, by the Griess Reaction [15]. This assay relies on
a simple colorimetric reaction between nitrite and Griess re-
agent (0.1% N-(naphthyl)ethylenediamine dihydrochloride,
1% sulfanilamide in 5% phosphoric acid) to produce a pink
azo product. Brieﬂy, a 50 ll aliquot of medium was mixed with
an equal volume of Griess reagent and incubated for 10 min at
room temperature. The absorbance was read at 550 nm using a
microtiter plate reader and compared with that of standard
sodium nitrite solution for quantitation.5. Western blotting
The cell lysates with equal amount of protein (i.e., 8 lg for
R134d, Tau-1 and DM1A, 10 lg for GSK-3b, 30 lg for
pS262 and pGSK-3b, and 40 lg for PHF-1) were ﬁrstly sepa-
rated by 10% SDS–polyacrylamide gel electrophoresis (PAGE)
and then electrophoretically transferred to nitrocellulose mem-
brane. Tau was probed with antibodies R134d (1:5000), Tau-1
(1:30000), PHF-1 (1:500), pS262 (1:1000), GSK-3b was probed
with anti-total-GSK-3b antibody (1:1000) and anti-GSK-3b
antibody speciﬁc to Ser9-phosphorylated form (1:1000),
a-tubulin was probed with DM1A (1:500). Immunoreactive
bands were then visualized by enhanced chemiluminescent
substrate kit and exposed to CL-XPosure ﬁlm. Protein bands
were quantitatively analyzed by Kodak Digital Science 1D
software (Eastman Kodak Company, New Haven, CT,
USA), and were expressed as sum optical density.6. Statistical analysis
Data were analyzed using SPSS 10.0 statistical software. The
one-way ANOVA procedure followed by LSDs post hoc tests
was used to determine the statistical signiﬁcance of diﬀerences
of the means.7. Results
7.1. Nonlinear dose-dependent release of nitric oxide from
SNP in culture medium
The level of nitric oxide in the culture medium was mea-
sured by Griess Reaction [15] after treatment of the cells
with diﬀerent doses (0, 0.25, 0.5, 1, 4, and 8 mM) of SNP
for 15 and 30 min, respectively. It was shown that the level
of nitrite, a stable metabolite representing the level of nitric
oxide released in the system, was increased in a nonlinear
dose-dependent manner with SNP concentration (Fig. 1),
which is consistent with previous report [16,17]. A signiﬁ-
cantly increased level of nitrite (P < 0.05) was shown when
the concentration of SNP reached 0.25 mM or higher and
about 80–85% of the nitric oxide was released in the ﬁrst
15 min after SNP administration. Pretreatment of the cells
by LiCl showed no remarkable eﬀect on the release of nitric
oxide from SNP (Fig. 1).7.2. Nitric oxide induces tau hyperphosphorylation at Ser396/
404 and Ser262 in HEK293/tau441 cells
The level of tau phosphorylation was measured after the
cells were treated with SNP at diﬀerent concentrations (0,
0.25, 0.5, 1, 4, and 8 mM) for 15 and 30 min, respectively.
As shown in Fig. 2, enhanced staining of tau at PHF-1
and pS262 epitopes, representing tau hyperphosphorylation
at Ser396/404 (PHF-1) and Ser262 (pS262) (P < 0.05), was
shown after SNP treatment. No obvious change was seen
at Tau-1 epitope (Ser199/202) as well as the level of total
tau (probed by R134d) (Fig. 2A). Quantitative analysis
showed that the elevation of tau phosphorylation was not
linear with increase of SNP concentration (Fig. 2B). To en-
sure that the altered phosphorylation of tau is due to nitric
oxide but not other chemicals released from SNP, we re-
peated the same experiment using nitric oxide-depleted
SNP (dSNP) (see Section 2) and found that the dSNP
showed no obvious eﬀect on tau phosphorylation
(Fig. 2C). This data conﬁrmed the role of nitric oxide in
tau hyperphosphorylation.
7.3. Nitric oxide activates GSK-3b in HEK293/tau441 cells
As glycogen synthase kinase-3b (GSK-3b) is the major ki-
nase responsible for tau phosphorylation at Ser396/404 (rec-
ognized by PHF-1) [18], we then estimated the activity of
GSK-3b by measuring the ratio of Ser9-phosphorylated
(i.e., inactivated form of the kinase [19]) to total level of
GSK-3b. As shown in Fig. 3A, the immunoreaction of
Ser9-phosphorylated GSK-3b was signiﬁcantly decreased in
a dose-dependent manner and such decrease is much more
obvious in the ﬁrst 15 min after SNP administration. These
results indicate that nitric oxide activates GSK-3b by reduc-
tion in phosphorylation at Ser9 under the experimental con-
dition used. No obvious change was seen in total level of
Fig. 2. Nitric oxide induces tau hyperphosphorylation at Ser396/404 and Ser262 in HEK293/tau441 cells. Equal amount of protein (i.e., 8 lg for
R134d, Tau-1 and DM1A, 40 lg for PHF-1 and 30 lg for pS262) were loaded each lane for Western blot (A,C) and quantitative analysis (B). The
level of Ser396/404 and Ser262 epitopes-phosphorylated tau was signiﬁcantly elevated, but no obvious change was seen in total tau (R134d) as well as
Tau-1 epitope-dephosphorylated tau and tubulin (DM1A). dSNP showed no obvious eﬀect on tau phosphorylation (C). The results are expressed as
the means ± S.D. (N = 3); \P < 0.05, \\P < 0.01 vs. controls (see Fig. 1).
Fig. 1. Nonlinear dose-dependent release of nitric oxide from SNP in culture medium. Nitrite, the stable metabolite of nitric oxide, in the culture
media was measured by Griess Reaction. The results are expressed as the means ± S.D. (N = 6); \P < 0.05, \\P < 0.01 vs. corresponding control (i.e.,
no SNP treatment at 15 and 30 min, respectively).
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Fig. 3. Nitric oxide activates GSK-3b in HEK293/tau441 cells. Equal amount of protein (10 lg for GSK-3b, and 30 lg for Ser9-phosphorylated
GSK-3b) were applied for Western blot (A,C) and for quantitative analysis (B). The signiﬁcantly decreased ratio of Ser9-phosphorylated GSK-3b
(i.e., the inactivated form) to total GSK-3b represents signiﬁcantly increased activity of the enzyme after SNP treatment. dSNP showed no obvious
eﬀect on the phosphorylation level of Ser9-GSK-3b. The results were expressed as the means ± S.D. (N = 3); \P < 0.05, \\P < 0.01 vs. controls (see
Fig. 1).
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iment was repeated by using nitric oxide-depleted SNP
(dSNP) and found that the dSNP has no obvious eﬀect on
GSK-3b Ser9 phosphorylation (Fig. 3C). These data sug-
gested that the activation of GSK-3b may be involved in ni-
tric oxide-induced tau hyperphosphorylation.
7.4. Inhibition of GSK-3b by LiCl partially attenuates nitric
oxide-induced tau phosphorylation at Ser396/404 in
HEK293/tau441 cells
To further conﬁrm the role of GSK-3b in nitric oxide-
induced tau hyperphosphorylation, we treated the cells with
10 mM LiCl, a widely used GSK-3 inhibitor [20,21], for 1 h
before SNP administration. We observed that the immuno-
reaction of Ser9-phosphorylated GSK-3b was dramatically
increased in the SNP group pretreated with LiCl (P < 0.05)
with no obvious change in the level of total GSK-3b. At
the same time, hyperphosphorylation of tau at PHF-1 sites
(P < 0.01) was also partially restored in LiCl treated group,
but no obvious change in total tau was seen (Fig. 4). It is
also observed that LiCl can also inhibits the basal GSK-
3b activity showing by increased level of Ser9-phosphory-
lated GSK-3b (Fig. 4). This data conﬁrmed that GSK-3b
activation is largely responsible for the nitric oxide-induced
tau hyperphosphorylation. As GSK-3b does not phosphory-
late Ser262 in vitro, we have not detected whether LiCl also
attenuated tau hyperphosphorylation at this site.8. Discussion
Abnormal hyperphosphorylation of tau is a pivotal lesion in
the pathogenesis of Alzheimers diseases (AD). The identiﬁca-
tion of upstream factors that induce tau abnormal hyper-
phosphorylation and the underlying molecular mechanisms
are among the major goals of research on AD. Increasing evi-
dence has shown that nitric oxide may be involved in the for-
mation of neuroﬁbrillary degeneration in AD brain [2–6,10];
however, direct evidence and the underlying mechanisms sup-
porting this notion are still lacking. Here we show that nitric
oxide can induce tau hyperphosphorylation at Ser396/404
and Ser262 sites in HEK293/Tau441 cells and GSK-3b activa-
tion is at least partially responsible for nitric oxide-induced
Alzheimer-like tau hyperphosphorylation at Ser396/404 sites.
Nitric oxide is produced by NOS. It is reported that during
the chronic progress of AD, overproduced b-amyloid (Ab)
can activate microglia and astrocytes and thus leads to NOS-
mediated production of nitric oxide [22–25]. Due to its free
radical properties, nitric oxide may in turn mediate Ab toxicity
and cause oxidative damage as seen in AD [26]. Taken together
the above information and the observation from this study, we
propose that tau hyperphosphorylation seen in AD brain
might be a downstream consequence of the reciprocal nitric
oxide-Ab mediated toxicity.
We choose SNP, a recognized donor of nitric oxide, as a di-
rect source of nitric oxide in this study. By incubating the cells
Fig. 4. Inhibition of GSK-3b by LiCl partially attenuates nitric oxide-induced tau phosphorylation at Ser396/404 in HEK293/tau441 cells. The cells
were pretreated with 10 mM LiCl for 1 h before SNP administration. The Western blots (A) and quantitative analysis (B) show that LiCl restores
Ser9-phosphorylated GSK-3b to normal level and concurrently prevents tau from SNP-induced hyperphosphorylation at PHF-1 epitope. The results
are expressed as the means ± S.D. (N = 3); \P < 0.01 vs. only SNP treatment of the corresponding doses. #P < 0.05, ##P < 0.01 vs. only LiCl
treatment of the corresponding doses.
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amount of nitrite, a stable metabolite used to evaluate the level
of nitric oxide, released from SNP to the culture medium was
increased dose dependently. LiCl, a GSK-3 inhibitor, showed
no signiﬁcant eﬀect on the production of nitric oxide from
SNP. With this data, we can use SNP as a liable nitric oxide
donor to study the eﬀect of nitric oxide on tau phosphorylation
and the underlying mechanisms.
After exposure of the cells to SNP, tau hyperphosphoryla-
tion at PHF-1 and Ser262 sites was observed. As GSK-3b is
the major kinase in phosphorylating PHF-1 sites (Ser396/
404) both in vitro and in vivo [18,27] and it is also a major
kinase implicated in abnormal tau hyperphosphorylation in
AD brain [28–31], we then detected the activity of GSK-3b
by activity-dependent antibody. We observed that the inacti-
vated form (i.e., Ser9-phosphorylated form) of GSK-3b was
decreased in a dose-dependent manner after SNP treatment,
and such decline was especially dramatic in the ﬁrst 15 min
of SNP treatment, suggesting activation and involvement of
GSK-3b in nitric oxide-induced tau hyperphosphorylation.
This involvement of GSK-3b was further conﬁrmed by
pretreatment of the cells with GSK-3 inhibitor, LiCl. As
80–85% of the nitric oxide was released in the ﬁrst 15 min,
we speculated that it might be the quick production of nitric
oxide rather than the total amount of the molecule responsible
for the activation of GSK-3b. This is consistent with the view-
point that it is the rate of nitric oxide ﬂux but not the net
amount of the molecule determining the ﬁnal eﬀect of nitric
oxide [32]. Further investigation is needed to verify whether
nitric oxide regulates GSK-3b activation in a ﬂux-dependent
manner in vivo.The level of nitric oxide and its derivatives, including perox-
ynitrite, is elevated during the chronic process of oxidative
stress in AD [33,34]. The relationship between nitric oxide or
oxidative stress and GSK-3b is not currently understood. It
is reported that peroxynitrite induces nitration of regulatory
subunit p85 of PI 3-kinase [35] and abolishes its interaction
with the catalytic subunit p110, and thus inhibits the activity
of PI 3-kinase [36]. PI 3-kinase is known to stimulate Akt/
PKB activity, which in turn inhibits GSK-3b by phosphorylat-
ing it at Ser9 [19]. Therefore, during the long process of oxida-
tive stress in AD, nitric oxide-derived species peroxynitrite
may overactivate GSK-3b by downregulating the PI 3-kinase
pathway [36] and thus lead to tau hyperphosphorylation at
GSK-3b sites. This may partially explain the mechanism that
nitric oxide activates GSK-3b.
We also noticed that treatment of the cells with SNP induced
enhancement in tau phosphorylation at Ser396/404 and
Ser262, but neither of these sites phosphorylation correlated
well with the concentration and duration of SNP exposure,
i.e., the hyperphosphorylation of tau was not positively corre-
lated with the increased level of nitric oxide. Recent study has
demonstrated that nitric oxide may regulate kinase activity
with distinct concentration threshold [37], suggesting that the
kinases involved in this nitric oxide-induced tau hyperphosph-
orylation may possess diﬀerent sensitivity to the amount of ni-
tric oxide. As tau phosphorylation is regulated by a balanced
regulation of various kinases and phosphatases, we believe
that in addition to GSK-3b, other kinase(s) must have also
participated in nitric oxide-induced tau hyperphosphorylation,
and this is especially true for Ser262, which is not a direct
GSK-3b site [38].
Y.-J. Zhang et al. / FEBS Letters 579 (2005) 6230–6236 6235In conclusion, we have demonstrated in the present study
that nitric oxide induces tau hyperphosphorylation at Ser396/
404 through GSK-3b activation in vitro. Nitric oxide may be
an upstream element of tau hyperphosphorylation in AD
pathology.
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